Background and Objective: Since the advent of mammography screening, ductal carcinoma in situ (DCIS) of the breast has been diagnosed increasingly. In contrast to the situation in invasive breast carcinoma, there are only a few reports on androgen receptor (AR) status in DCIS and few reports on estrogen ...

Objective(s): Studies have reported that invasive ductal carcinoma (IDC) with coexisting ductal carcinoma in situ (DCIS) show lower metastatic potential and recurrence and better overall survival than pure IDC. In this study, we assessed F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imagesof patients with newly diagnosed IDC to...

BACKGROUND Breast ductal cancer in situ (DCIS) can recur or progress to invasive ductal cancer (IDC), and the interim stage include DCIS with microinvasion (DCIS-Mi). In this article, we attempt to study the study the differences of clinicopathological features, imaging data, and immunohistochemical-based subtypes among DCIS, DCIS-Mi, and IDC. METHODS In this retrospective study, we attempt t...

background and objective: since the advent of mammography screening, ductal carcinoma in situ (dcis) of the breast has been diagnosed increasingly. in contrast to the situation in invasive breast carcinoma, there are only a few reports on androgen receptor (ar) status in dcis and few reports on estrogen (er) and progesterone (pr) receptors. materials and methods: ar expression was examined in 5...

BACKGROUND Ductal carcinoma in situ with microinvasion (DCIS-Mi) generally has favorable prognosis, but the long-term outcomes of DCIS-Mi and the biologic evolution from ductal carcinoma in situ (DCIS), DCIS-Mi, to DCIS with T1a breast cancer (DCIS-T1a) has not been specified. The aim of our study was to explore the biological and prognostic features of DCIS-Mi, compared with pure DCIS and DCIS...

Background The prognostic implication of concomitant ductal carcinoma in situ (DCIS) in invasive ductal carcinoma (IDC) remains controversial. Our objective was to investigate whether concomitant DCIS affects survival outcomes in patients with IDC. Materials and methods Patients with nonmetastatic breast cancer who underwent surgery in 2010-2014 were included from the Surveillance, Epidemiolo...

Although ductal carcinoma in situ (DCIS) precedes invasive ductal carcinoma (IDC), the related genomic alterations remain unknown. To identify the genomic landscape of DCIS and better understand the mechanisms behind progression to IDC, we performed whole-exome sequencing and copy number profiling for six cases of pure DCIS and five pairs of synchronous DCIS and IDC. Pure DCIS harbored well-kno...

When breast screening began in the UK, such was the uncertainty concerning the benefi ts and harms of detecting ductal carcinoma in situ (DCIS) that national guidelines specifi ed an upper limit as well as a lower limit for detection by individual screening centres. This was only changed when an association was shown between DCIS detection and small invasive cancer detection in the National Hea...

The focus of this study was to determine if early detection of mutant p53 accumulation may be an early indicator of tumor aggressiveness and transformation to invasive breast cancer. For this purpose, the p53 content of 100 human breast biopsies classified as ductal carcinoma (DCIS), was evaluated by immunohistochemical method. All specimens were microscopically classified into histologic types...

The authors retrospectively aimed to determine which of the following three scenarios, related to DCIS entry into BRCAPRO, predicted BRCA mutation status more accurately: (1) DCIS as an invasive breast cancer (IBC) entered using the actual age of diagnosis, (2) DCIS as IBC entered with 10 years added to the actual age of diagnosis, and (3) DCIS entered as no cancer. Of the 85 DCIS patients incl...